Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure

Evaluation of target organs impairment on patients suffering from high blood pressure without known cardio vascular or renal disease, stratified on blood pressure control.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blood Pressure Cardiovascular Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hypertension Kidney Diseases Male Urogenital Diseases Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Abbeville, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults with hypertension (treated or not), without known cardiovascular or renal disease.

Treatment and study plan

Primary outcomes

To evaluate the frequency of evaluation of target organs preclinical impairment on patients without known cardiovascular or renal disease, taking into consideration the blood pressure level (controlled HBP or not)

Time frame: Once

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure Without Known Cardio Vascular or Renal Disease, Stratified on Blood Pressure Control.

Acronym: PREVENTA

Important dates

Study start: 2009
Study completion: 2009
First posted: Jun 22, 2009
Registry last updated: Dec 18, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed